30 August 2017AmericasWenhua Yu, Stephen Maebius and Tianran Yan
Data analysis: the highs and lows of generic-filed IPRs
We reviewed a sub-group of 204 inter partes reviews (IPRs) filed by generic drug companies against pharmaceutical patents to assess Patent Trial and Appeal Board (PTAB) outcomes and key trends in dealing with this technology field. The study captured IPR filings by 14 of the most active generic petitioners among the world’s top-20 generic drug companies.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
19 March 2026 Although the court agreed that the tech giant misappropriated some of Masimo’s information related to pulse oximetry technology, Apple is not barred from using it, says a California judge.
17 March 2026 Janssen seeks injunctive relief after a forensic review uncovers mass downloads of trade secrets spanning oncology, neuroscience and immunology portfolios.
12 March 2026 The event unpacked how technology, litigation trends, and global events are adding complexity while also offering benefits for legal teams under pressure to reduce costs.